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ABSTRACT: Selective covalent inhibition of kinases by targeting poorly conserved cysteines has proven highly fruitful to 
date in the development of chemical probes and approved drugs. However, this approach is limited to ~200 kinases pos-
sessing such a cysteine near the ATP-binding pocket. Herein, we report a novel approach to achieve selective, irreversible 
kinase inhibition, by targeting the conserved catalytic lysine residue. We have illustrated our approach by developing se-
lective, cov  ?Ɉ        ǡ       ? ? ?  
CD4+ T cells. Despite conservation of the lysine residue throughout the kinome, the lead compound shows high levels of 
selectivity over a selection of lipid and protein kinases in biochemical assays, as well as covalent binding to very few off-
target proteins in live-cell proteomic studies. We anticipate this approach could offer an alternative general strategy, to 
targeting non-conserved cysteines, for the development of selective covalent kinase inhibitors. 
INTRODUCTION 
The clinical successes of ibrutinib1 and afatinib2 have 
prompted a resurgence of interest in covalent drug dis-
covery.3,4 Covalent inhibitors can possess the advantages 
of increased potency, prolonged duration of action, de-
coupled pharmacodynamics and pharmacokinetics, and, 
often, require less frequent and lower doses.4,5 
In the kinase field, researchers commonly target cyste-
ine residues for covalent inhibition.6 Targeted residues 
ǲ-ǳ7 to maxim-
ise selectivity, and mitigate the risk of off-target covalent 
interactions.4,5,7,8 However, only ~200 of over 500 human 
kinases have been mapped with a cysteine in the vicinity 
of the ATP pocket, and <50 have been demonstrated to 
covalently engage with inhibitors, restricting the scope of 
this strategy.6,9Ȃ11 We chose to challenge this general ap-
proach by investigating the potential to selectively and 
irreversibly target the kinome-conserved lysine residue.12 
Covalent conjugation with lysine is far less common, due 
to its protonation state, and therefore poorer nucleo-
philicity under physiological conditions.13 Nonetheless, 
interest in this nucleophile is rapidly gaining traction in 
the scientific community.14Ȃ18  
The heterodimeric lipid kinase phosphoinositide 3-
ȋ ?ɈȌ19,20 has been targeted specifically over 
 ?ɄǡɅɇ
variety of diseases.21,22 A number of selective reversible 
 ?Ɉi-
als, with Zydelig recently obtaining FDA approval as a 
second-line treatment for relapsed follicular B-cell non-
Hodgkin lymphoma, and relapsed chronic lymphocytic 
leukemia.23Ȃ25 More recently, drug developers have target-
  ?Ɉ      
such as asthma, chronic obstructive pulmonary disease 
ȋȌǡ      ?Ɉ n-
drome.21,26Ȃ32 
ǡ ?Ɉ 
has not yet been disclosed, and there is no obvious iso-
form specific nucleophilic residue to target around the 
ATP binding site. Irreversible pan-PI3K inhibitors have 
been investigated previously, based on the fungal antibi-
otic wortmannin.33Ȃ35 These compounds target the con-
served lysine12,36,37 for the covalent reaction, but are poorly 
selective.35 Promiscuous kinase probes that covalently 
bind to this residue,38Ȃ41 have also been developed and 
commercialised, however methods of selectively targeting 
this lysine in specific kinases have not yet been reported.  
Herein we describe the development of the first selec-
ǡ   ?Ɉ ǡ    
   ȋ ? ? ?   ?Ɉ ȌǤ
Selectivity was achieved through optimisation of the re-
versible interactions in formation of the initial enzyme-
2 
inhibitor complex, whilst the rate of the covalent reaction 
with the protein remained constant. The targeted lysine 
residue is present throughout the kinome, hence we an-
ticipate that this strategy could provide an alternative 
general approach for the development of selective irre-
versible kinase inhibitors.  
RESULTS AND DISCUSSION 
Design of lysine targeting inhibitors. Clinical candi-
date 1 was identified as a suitable starting point due to its 
potency profile, and reversible interaction between the 
sulfonamide and Lys779.23 We replaced the cis-
dimethylmorpholine with the more basic, more soluble 
piperazine moiety23 and hypothesised that substitution of 
the sulfonamide for an electrophilic functional group 
could afford covalent inhibitors (Figure 1). In silico mod-
elling suggested that activated esters42 would be tolerated 
in a reversible enzyme-inhibitor complex with PI3KɈ. Fur-
thermore, the model of the covalently bound amide ad-
duct that would form from these inhibitors did not reveal 
any obvious conformational issues (Figure S1). 
Figure 1. Generalised design principles for development of 
selective, irreversible PI3KɈinhibitors.  
     ?Ɉ   
and cellular assays. A selection of phenolic esters were 
ǡ ?ɄǡɅǡɇɈ
assessed using purified recombinant proteins via homo-
geneous time-resolved fluorescence (HTRF) assays.23 Ad-
ditionally, these compounds were tested in a phenotypic 
human-whole blood (hWB) assay, measuring reduction in 
  ȋ	ɇȌ    
T-cell stimulating antibody, CytoStim, as a readout for 
 ?Ɉngagement23 (Table 1).  
Esters 2-7   ?Ɉ  
assays with pIC50 values ranging from micromolar (ester 
7), to sub-nanomolar (ester 2), confirming that the phe-
nolic ester motifs were tolerated in the ATP binding 
pocket of the kinase. Furthermore, these data suggested a 
    ?Ɉ    itors im-
proved with the electron withdrawing ability of the R 
ǡ ?Ɉ
activity of 2 was achieved at the expense of selectivity. 
The 4-trifluoromethylphenol ester 3 is an exception to 
this trend. Its relatively strong electron withdrawing ef-
 ȋɗp = 0.78, 0.54, 0.06 and -0.27 for NO2, CF3, F, and 
OMe substituents)43      ?Ɉ 
compared to the electron neutral phenol 5. The decreased 
potency of 2,4-dimethylphenol ester 7 may have arisen 
from clash between the 2-methyl group and the kinase, or 
steric hindrance to nucleophilic attack at the carbonyl. 
Compounds 3 to 5 showed the best profiles in this analy-
sis, with biochemical potencies on-par with wortmannin 
10, and selectivity comparable to the FDA-approved 
 ?Ɉ ǡ 24 11. Furthermore, compounds 3-5 
provided good levels of inhibitory activity in the hWB 
assay (~10 nM), supporting engagement o ?Ɉǡ
and were at least 15-fold more potent than 10 and 11 in 
this assay. It is worth noting that covalent inhibition is a 
time-dependent process, and the pIC50 values would be 
expected to vary with time. The biochemical assays were 
read-out at 1 h in all cases, and the hWB assay at 20 h to 
provide consistency for data analysis.  
Table 1. Compounds 2- ? ?Ɉ
and cellular assays.  
 
Cpd 
pIC50
a 	ɇ
pIC50
b Ɉ Ʉ Ʌ ɇ 
1 9.1 6.3 6.2 6.3 8.5 
2 9.2c 8.2 c 7.2 c 5.8 c N.T 
3 8.3 5.6 5.1 4.6 8.1 
4 8.1 5.5 5.3 4.8 7.9 
5 8.2 5.6 5.4 4.9 7.9 
6 7.3 4.8 4.9 5.0 7.4 
7 6.4 5.1 4.8 5.0 6.9 
8 7.4 5.0 <4.5 <4.5 7.0 
9 7.9 4.9 4.7 4.8 5.0 
10 
Wortmannin 
8.3 8.1 8.0 8.2 6.7 
11 
Zydelig 
8.1 5.0 5.8 6.6 6.7 
a
Biochemical pIC50 data for all inhibitors at all four PI3K 
isoforms (measured after 1 h at KM(ATP) using HTRF assays). 
b
Phenotypic hWB pIC50 derived from measuring levels of 
	ɇ  (20 h incubation, free 
compound concentrations are not available). Data for pan-
covalent PI3K inhibitor wortmannin 10, and FDA approved 
 ?Ɉ ǡ    11 derived from 
these assays are also shown. 
c
Compound found to be particu-
larly unstable in DMSO, results reported from N = 2 only. 
N.T: Compound not tested due to instability of the DMSO 10 
mM stock solution. All compounds were tested a minimum 
of three times in HTRF and hWB assays, with the exception 
of compounds 2, 8 and 9 (Table S1). 
Protein mass spectrometry and reactivity assess-
ments indicated the potential for site-specific nucle-
ophilic trapping by a lysine residue. After 5 min incu-
    ?Ɉ  4 (2:1 molar ratio of 
4ǣ ?ɈȌ, we observed formation of a single adduct by 
3 
intact protein liquid chromatography-mass spectrometry 
(LCMS). Compared to untreated protein, this mass shift 
was consistent with the addition of 4, and loss of 4-
fluorophenol. Repeating this assay with 10 molar equiva-
lents of 4, and 20 h incubation showed no additional ad-
duct formation. Pre-   ?Ɉ   ? ? a-
lents of the potent ATP-competitive reversible inhibitor23 
12 prevented formation of the covalent adduct, suggesting 
covalent modification occurred in the ATP binding site. 
Carboxylic acid 9 showed no evidence of covalent bond 
formation in this experiment, implying that the phenolic 
ester was required for the covalent reaction. These results 
suggested that 4 was covalently, and specifically, binding 
 ?ɈȋFigure 2a). 
Reactivity analysis showed that 4 was stable to hydroly-
sis and reaction with N-Boc lysine under physiological 
conditions (phosphate buffer, pH 7.4, 37 °C), but upon 
deprotonation of the lysine smooth amide bond for-
mation was observed (Figures S2 and S3). Together with 
the mass spectrometry data suggesting that a single, spe-
 ?Ɉǡ
proposed that this bond could be forming with the con-
served lysine. 
Confirmation of Lys779 as the nucleophilic residue. 
After overnight soaking of pre-grown murin ?Ɉs-
tals20,23 with 4, we observed a covalently bound adduct 
between the inhibitor and the targeted lysine residue 
(Figure 2b) by X-ray crystallography. Continuous elec-
tron density was seen between Lys779 and the carbonyl of 
the ester, and there was no evidence for the phenolic 
group being present, consistent with formation of an am-
ide bond. Methyl ester 8 showed a reversibly bound ad-
duct (Figure S4), consistent with the reduced reactivity 
of this ester (Figure S2). The remainder of the compound 
satisfied the desired hydrogen bonding interactions be-
tween the indazole and hinge residues Val828 and 
Glu826, as well as occupying the selectivity region next to 
Trp760 with the basic amine.23,44 
Time-course experiments to determine kinact and 
KI. Using the commercially available ADP Quest
TM assay 
kit45 we derived the concentration of inhibitor required 
for half of the maximum rate of covalent bond formation 
(KI), the rate constant for irreversible inactivation (kinact) 
and the second order rate constant typically used to char-
acterise irreversible inhibitors (kinact/KI) (Figure 2f).
4,46Ȃ48 
Full analyses for esters 2-7 and 10, including equations 
used, are detailed in the Supporting Information. 
All six esters exhibited non-linear reaction progress 
curves (Figure 2c and Figure S7) indicating time-
    ?Ɉǡ   
inactivation. The kinact/KI ranking obtained from the 
replot method correlated well with the potencies ob-
    ?Ɉ    
(Table 1 and Figure S7). The kinetic data were visualised 
by plotting kinact as a function of KI, as described by 
Schwartz et al. (Figure 2e).49 This representation clearly 
showed that similar kinact values were found for all six es-
ters (1.4-fold difference across the series), but KI differ-
ences spanned two orders of magnitude, from 40 nM 
(compound 2) to 7.8 µM (compound 6) (195-fold differ-
ence, Figure 2f). This indicated that the electronic nature 
of the phenolate leaving group (i.e. pKa value), and there-
fore expected chemical reactivity/leaving group ability, 
does not correlate with the rate of the covalent inactiva-
tion in this system. Rather, there is a correlation with KI, 
suggesting a more complex mechanism than the tradi-
tional two-step scheme depicted in Figure 2e. The differ-
ences in pIC50 between the esters in our biochemical assay 
must therefore be dictated by reversible interactions in 
formation of the initial enzyme-inhibitor complex and 
not the rate of the covalent reaction. We have proposed a 
reaction mechanism supporting these data, invoking ad-
ditional steps to explain the dependence of KI on pKa 
(Supplementary Discussion and Scheme S1). Finally, 
our prior analysis of the chemical reactivity of 4 (Figures 
S2 and S3) showed it to be inert to nucleophilic substitu-
tion under physiological conditions. This suggested that 
the elevated reactivity observed in these kinetic analyses 
was occurring specifically in the protein, and that the lo-
cal microenvironment around Lys779 may be contrib-
uting to an increased reactivity of this residue, rendering 
it hyper-reactive.16,37,50,51 
Selectivity, despite the conserved lysine, is driven 
by reversible interactions. To assess off-target covalent 
binding, jump dilution and kinetic measurements at two 
   ?  ȋɄ  ɅȌ   
with 4. All three enzymes were inactivated in the jump 
dilution experiment without competing ATP indicating 
that 4  ?ɄǡɅɈe-
incubation concentrations (Table S3), without a compet-
ing ligand (Figure 3a). As controls, the experiment was 
performed with covalent pan-PI3K inhibitor 10, and re-
versibly bound ester analogues 8 and 9. 10 showed cova-
lent inactivation of all three kinases, whereas 8 and 9 
showed the expected regeneration of enzyme activity af-
ter dilution, consistent with a reversible mode of inhibi-
tion (Figure 3a and Table S4).  
However, in the kinetic analysis with competing ATP (1 
Ȍǡ ?Ʉ
ɅȋTable S6). The gradi-
ent of these plots decreased with increasing concentration 
of inhibitor, consistent with a rapid onset of inhibition. 
The absence of the slow-binding non-linear phase we had 
 ?Ɉc-
curring at these kinases under these conditions. Indeed, 
for ester 4ǡ     ?Ɉ 10, whilst the 
   ?Ʉ  Ʌ    
methyl ester 8 (Figure 3b). This absence of apparent co-
 ?ɄɅ ?Ǥ ?
ɑ4ǡ ? ? ?Ɉ99 ȋ ? ?Ǥ ? ?ɑȌn-
ditions. Reprocessing the raw data along the time axis 
allowed derivation of IC50 values every 30 s over this time 
window. These plots showed a time-dependent decrease 
in IC50  ?Ɉǡ ?ɄɅ4 (Figure S8), 
supporting selective covalent inhibition in this assay. 4 
also exhibited excellent selectivity against a panel of 10 
lipid kinases and 140 protein kinases (Tables S7 and S8).    
4 
 
Figure 2. Compounds 2-7  ?Ɉ ? ? ?ǡ
recognition. (a) Protein mass spectrometry. Top to bottom Ȃ apo protein; protein treated with two equivalents of 4, analysed at 5 
min; protein treated with 10 equivalents of 4 overnight; protein pre-treated with 10 equivalents of 12 for 15 min, prior to addition 
of two equivalents of 4, and analysed at 5 min; protein incubated with 10 equivalents of 9 and analysed at 5 min. (b) Left: Crystal 
structure of 4  ?Ɉ (PDB: 6EYZ). Right: Fo-Fc omit map is shown in green at 2.7 rmsd, with 
Lys799 side-chain and ligand co-ordinates removed, showing clear electron density from Lys779 onto the ligand. (c) Raw time-
course data for 4. Concentrations are shown after correction for absolute stock concentration using quantitative NMR (Table 
S5). (d) Plot of derived kobs from (b) vs concentration of inhibitor to derive KI and kinact. (e) Plot of derived kinact vs KI for all 6 
esters, and wortmannin.
4,46
 (f) Table of kinact, KI and kinact/KI values. Kinetic measurements were performed in triplicate, and data 
are shown as the mean ± s.e.m. 
These kinetic and jump dilution analyses revealed a 
concentration window where 4 covalently inactivated 
 ?Ɉǡ        
family, despite the conserved nature of the nucleophilic 
amino acid. Upon saturating the ATP binding site with 
high concentrations of inhibitor, in the absence of com-
peting ATP, covalent inactivation does occur. However, in 
a cell- ǡ     ?Ʉ
 Ʌ       ?   ?Ɉ 99. Con-
sistent with our
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Figure 3. 4  ?ɄɅ ? ?Ɉ99 with cellular concentrations of ATP. (a) Jump dilutions 
 ?ɄȋȌǡ ?ɅȋȌ ?ɈȋȌǤ Covalent inactivation of all three 
kinases was observed under these conditions by 4. Inhibitor assays were conducted in triplicate and controls in duplicate. Re-
sults are plotted as mean ± s.e.m (b) Kinetic plots of the inhibition over time under saturating ATP conditions (1 mM). Linear 
plots (blue) relative to no-inhibitor controls (black) are typical of reversible inhibitors. Non-linear plots (red) relative to no-
inhibitor controls (black) are typical of slow-binding inhibitors (confirmed to be irreversible by jump dilution experiments in 
(a)). The top row depicts reversible ester 8, showing linear progress at IC90  ?Ɉǡ ?ɄɅ ?Ɉ99. Mid-
dle row depicts irreversible inactivation of all three kinases by wortmannin at IC90  ?Ɉ ȋ ?Ǥ ?  ?Ɉ 90 curves are also 
shown). Bottom row shows selective ester 4, exhibi ?Ɉ90ǡ ?Ʉ
Ʌ ? ? ?Ɉ99. Assays were conducted in duplicate, and results are shown as mean ± s.e.m. 
earlier observation that potency differences between the 
   ?Ɉ     ǡ
this selectivity must also arise from differences in the ini-
tial reversible binding interactions (KI) with these kinases. 
Chemoproteomics revealed 4 to be selective for 
PI3KɈ in live cells. Azido probe 13 was synthesised, and 
retained potency at PI3KɈ in the biochemical HTRF assay 
(pIC50 = 7.6). At  ?ɑ, it was shown to covalently modify a 
protein with a molecular weight consistent with PI3KɈ in 
THP-1 monocyte lysates by in-gel fluorescence after 
strain-promoted azide-alkyne cycloaddition click reaction 
(SPAAC) with dibenzycyclooctyne-conjugated-Cy5 dye 
(DBCO-Cy5), and SDS-PAGE separation. Co-elution of 
PI3KɈ with the Cy5 signal was confirmed by im-
 ? ? ?Ɉ	
membranes (Figure S9).52 Furthermore, the Cy5 fluores-
cence signal was gradually ablated in the presence of in-
creasing concentrations of 4, with a pIC50 of 7.5, suggest-
ing  ?Ɉ4 in complex cell ly-
sates. 
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Figure 4. Chemoproteomic analysis identifies targets of 4 in human cells. (a) General assay design. (b) Structures of 4 and 13, 
and key for graphs below. (c) The scatter plots display proteins enriched with neutravidin beads after clicking a biotin moiety to 
proteins labeled in situ with probe 13 ȋ ?ɑȌǤ
SDS elution from the bead. The dotted lines represent 2-fold enrichment (13/DMSO) and proteins with >2-fold enrichment are 
deemed specific targets of 13, and are labeled by their entrez gene ID. (d) Dose-response curves for competition of 13 binding to 
specifically enriched targets after pretreatment of cells for 1 h with 4. Binding curves and resulting pIC50 values are shown for 
proteins enriched >2-fold. With the exception of FECH, values are not plotted if no binding curve could be fitted using 
GraphPad Prism 7.03. The values represented are the average ± s.e.m. from two biological replicates. In (c) and (d), data were 
filtered with the criteria that quantified unique peptide matches > 1 and quantified unique peptide to spectra matches >2. Pro-
teins were required to be identified and quantified in both replicates to be included in the analysis, and data are plotted as the 
mean of the TMT label ratios (MS
2
) for the three most abundant peptides (MS
1
) per protein.
Protein targets of probe 13 in Ramos cells were then 
identified by a quantitative mass spectrometry-based 
chemoproteomics method using tandem mass tag (TMT) 
labelling (Figure 4a), based on related experiments by 
Lanning et al53 and Niessen et al.54 Cells were treated with 
either vehicle or 13 at 1 ɑM for 1 h, lysed, and proteins 
bound by 13 were enriched with neutravidin beads after 
SPAAC reaction with a DBCO-biotin conjugate. Non-
covalently bound proteins were expected to be predomi-
nantly eluted with SDS, whereas covalent targets should 
only be detected after on-bead proteolysis.  
Comparison to vehicle-treated cells identified 22 out of 
~1000 identified proteins that were specifically enriched 
>2-fold by in situ treatment with 13 (Figure 4c and Sup-
plementary Data Set). Of those 22 proteins, eight were 
exclusively identified after direct proteolysis, including 
the class I catalytic subunits of PI3KɈ (gene ID PIK3CD), 
 ?Ʉ ȋ   ?Ȍǡ  ?Ʌ ȋ   ?Ȍǡ 
the class III PI3K protein Vps34 (gene ID PIK3C3), sug-
gesting these proteins as covalent targets of 13. In con-
trast, the Vps34 regulatory subunits55 PI3K regulatory 
subunit 4 (gene ID PIK3R4), Beclin-1 (gene ID BECN1), 
p63 (gene ID UVRAG), mitofilin (gene ID IMMT), and 
protein RUBCNL-like (gene ID C13ORF18) as well as the 
common kinase inhibitor off-target ferrochelatase56 (gene 
ID FECH), were only found in the SDS eluates. The possi-
bility to elute those proteins from the capturing matrix 
with SDS buffer implicates those proteins as reversible 
binders of 13, or proteins in complexes with enriched tar-
gets. The PI3K Ʉȋ ? ?Ȍ
identified in the bead digest fraction as well as in the SDS 
eluates. Signal abundances of detected tryptic peptides 
(MS1 intensities) indicated a 3 to 4-fold higher abundance 
in the SDS fraction than in the bead digests. This suggests 
major, but incomplete, elution of this known interactor of 
class I catalytic PI3K subunits26 with the applied condi-
tions.  
To accurately assess off-target interactions of 4, we de-
rived dose-response curves from competing the binding 
to 13 by pretreatment with concentrations of 4 ranging 
from 10 µM to 3.2 nM for 1 h (Figure 4d). For the specifi-
cally enriched proteins exclusively found in the bead di-
gests, we calculated pIC50 values for PI3Ɉǡ ?Ʉǡ ?Ʌǡ
and hVps34 to be > 8.5, 7.0, 6.9 and 7.2, respectively. This 
      ?Ɉ  13 can be 
competed by 4 with >20-fold selectivity at the used incu-
7 
bation conditions. For the proteins identified exclusively 
in the SDS fraction, we determined reasonable binding 
curves for Beclin-1, p63, and PI3K regulatory subunit 4. All 
resulted in very similar pIC50 values (pIC50,BECN1 = 6.8; 
pIC50,UVRAG = 6.6; pIC50,PIK3R4 = 6.6). Binding curves were 
incomplete for those proteins (maximal competition by 
10 µM compound c.a. 50%), suggesting they were interact-
ing with a known complex partner,55 rather than being 
true targets of the compound. A similar effect might be 
 ? Ʉ pIC50 
value >8.5 was determined. As a complex partner of 
 ?Ʉǡ ?Ʌǡ ?Ɉǡ26 the determined apparent dose-
dependent competition may result from a combination of 
competitive binding to any of these PI3K proteins. Within 
the tested concentration range, mitofilin, ferrochelatase, 
and protein RUBCNL-like, (as well as the remaining pro-
teins that were specifically enriched with 13) did not show 
strong competition of binding by 4, suggesting low affini-
ty binding.   
These chemoproteomic data support minimal off-target 
binding by 4 in human cells. Coupled with our selectivity 
hypothesis and kinase panel investigations above (Figure 
3 and Tables S7 and S8), we propose 4 to be a highly se-
lective irreversible inhibitor of PI3KɈ at concentrations 
below 1 ɑM. 
Cellular washout studies suggest an extended du-
ration of action. CD4+ T cells were incubated with 4 or 
12 (hWB pIC50 = 7.9) for 2 h, then washed and incubated 
    ? ?     Ʉ ? 
 	ɇǤ4 showed sustained deple-
  	ɇ   ? ?   ǡ  o-
toxic effects (Figure S10), whereas rege  	ɇ
secretion was observed for 12 (Figure 5). These results, 
taken together with the data presented above, suggest 
that inhibition of PI3Ɉ ? ?
h using an irreversible targeting approach, with no cyto-
toxic effect. It is worth noting, however, that cellular ac-
cumulation of dibasic piperazines could also be a contrib-
uting factor to the duration of action for this series of 
compounds.57,58 
 
Figure 5. Inhibitor 4 showed a prolonged duration of action, 
up to at least 48 h in CD4+ T cells. Cellular washout studies 
conducted in CD4+ T cells isolated from hWB. Cells were 
treated with inhibitors for 2 h, washed, and stimulated with 
Ʉ ? 	ɇǡ  ? ?Ǥ Left: Co-
valent compound 4 showed a clear sustained duration of 
action (black circles) 48 h after washing. Right: Reversible 
compound 12 showed a clear disruption of the inhibition 
profile (black circles) 48 h after washing. The experiment was 
repeated using 5 donors (for each donor: N = 3 replicates for 
washout, and N = 2 replicates for non-wash condition), and 
results are depicted as mean ± s.e.m. Non-washed curves 
showing the dose-response after 48 h are shown in blue. 
 
 
CONCLUSION 
Selective covalent inhibition relies on a two step pro-
cess of reversible binding and then covalent 
inactivation.4,5 Here, we have demonstrated that selectivi-
ty in formation of the initial enzyme-inhibitor complex is 
the crucial factor for achieving potent, selective covalent 
inhibition of conserved residues. Kinetic studies indicated 
that the electronics, and expected chemical reactivities, of 
the electrophilic esters did not affect the rate of covalent 
bond formation with the enzyme, kinact. The observed var-
 ?ɈȋTable 1) therefore 
arose from the reversible binding steps of the inhibitors, 
due to electronic changes in the phenolic group, reflected 
by KI. 	ǡ      ?Ʉǡ Ʌǡ
Ɉn-
tration range at which covalent inhibitio ?Ɉ
be achieved, without covalent inactivation of related en-
zymes. This was confirmed by chemoproteomic studies 
with 13 in situ which suggested minimal off-target binding 
of 4, and a >20-fold selectivity window for covalent modi-
fication of  ?Ɉ, despite conservation of the targeted 
lysine residue and presence of other reactive moieties. 
As a more general approach, variation of the electro-
philic centre to affect reversible binding could be exploit-
ed for fine-tuning of the potency, selectivity, and physico-
chemical properties of inhibitors for irreversible drug dis-
covery programmes. By maintaining a constant kinact  
across a series of electrophilic esters, this provides an or-
thogonal approach to established EGFR and Janus Kinase 
(JAK) inhibitors that vary the kinact to improve the drug 
profile.8,59 Furthermore, a common method for enzymes 
to develop resistance to covalent inhibitors targeting 
poorly conserved cysteines is by point mutation of the 
modified residue.60 A similar resistance mechanism would 
not be applicable to the strategy we have developed, as 
mutation of the catalytic lysine would render the kinase 
inactive.61 Finally, the potential lability of these esters 
could impart kinetic selectivity in vivo. Zaro et al. recently 
described how the proteome-wide selectivity of ibrutinib 
improved when a fumarate ester was incorporated into 
the covalent warhead. They attributed this to hydrolysis 
of the metabolically labile ester, affording an inert 1,4-
unsaturated carboxylate.62 Carboxylic acid 9 formed in 
our case is poorly active in the cellular assay (pIC50 = 5.0, 
Table 1), and inert to covalent bond formation by mass-
spectrometry (Figure 2a), suggesting a similar mecha-
nism could be observed here. 
By modification of a known reversible inhibitor,23 we 
have developed a series of esters which selectively and 
   ?ɈǤ      e-
lectivity profile, our lead compound 4 showed ~10 nM 
activity in the hWB phenotypic inflammatory cytokine 
response assay, and extended duration of action (>48 h), 
in cellular washout studies. Owing to the importance of 
8 
 ?Ɉǡe-
ǡ   ?Ɉ    s 
in the development of long-acting therapeutics. 
Prior studies have shown that the targeted conserved 
lysine reacts covalently with promiscuous probes pos-
sessing reactive warheads.38Ȃ41 We therefore envisage that 
this approach could be orthogonal to non-conserved cys-
teine targeting, and applicable across the kinome. By this 
method, researchers may be able to generate selective 
covalent chemical probes of any chosen kinase, which 
could provide tools to vastly improve the understanding 
of human biology in diseased states. 
ASSOCIATED CONTENT  
Supporting Information.  
Biological methods, synthetic methods and characterisation, 
supplementary figures, supplementary tables, supplementary 
mass-spectrometry tables, and supplementary discussions.  
AUTHOR INFORMATION 
Corresponding Author 
* sebastien.x.campos@gsk.com 
Author Contributions 
All authors have given approval to the final version of the 
manuscript.  
 
Notes 
The authors declare no competing financial interests. 
ACKNOWLEDGMENT  
We thank the GlaxoSmithKline/University of Strathclyde 
Industrial PhD programme for funding this work. We also 
thank D. House for providing revisions of the manuscript, 
J.N. Hamblin and V. Patel for intellectual discussions, and N. 
Barton, C. Chitty, P. Francis, L. Gordon, N. Hodnett, S. 
Kumper, S.M. Lynn, J.E. Rowedder, E. Sherriff and H. Taylor 
for technical assistance and discussion. 
REFERENCES 
(1)  Kim, E. S.; Dhillon, S. Drugs 2015, 17, 769Ȃ776. 
(2)  Hossam, M.; Lasheen, D. S.; Abouzid, K. A. M. Arch. Pharm. 
Chem. Life Sci. 2016, 349, 1Ȃ21. 
(3)  Bradshaw, J. M.; McFarland, J. M.; Paavilainen, V. O.; 
Bisconte, A.; Tam, D.; Phan, V. T.; Romanov, S.; Finkle, D.; 
Shu, J.; Patel, V.; Ton, T.; Li, X.; Loughhead, D. G.; Nunn, P. 
A.; Karr, D. E.; Gerritsen, M. E.; Funk, J. O.; Owens, T. D.; 
Verner, E.; Brameld, K. A.; Hill, R. J.; Goldstein, D. M.; 
Taunton, J. Nat. Chem. Biol. 2015, 11, 525Ȃ531. 
(4)  Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. Nat. Rev. 
Drug Discov. 2011, 10, 307Ȃ317. 
(5)  Baillie, T. A. Angew. Rev. 2016, 55, 2Ȃ17. 
(6)  Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, 
L. H.; Gray, N. S. Chem. Biol. 2013, 20, 146Ȃ159. 
(7)  Mah, R.; Thomas, J. R.; Shafer, C. M. Bioorganic Med. Chem. 
Lett. 2014, 24, 33Ȃ39. 
(8)  Nacht, M.; Qiao, L.; Sheets, M. P.; Martin, T. S.; Labenski, 
M.; Mazdiyasni, H.; Karp, R.; Zhu, Z.; Chaturvedi, P.; 
Bhavsar, D.; Niu, D.; Westlin, W.; Petter, R. C.; Medikonda, 
A. P.; Singh, J. J. Med. Chem. 2013, 56, 712Ȃ721. 
(9)  Zhang, J.; Yang, P. L.; Gray, N. S. Nat. Rev. Cancer 2009, 9, 
28Ȃ39. 
(10)  Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J.-M.; 
Winssinger, N. J. Med. Chem. 2011, 54, 1347Ȃ1355. 
(11)  Zhao, Z.; Liu, Q.; Bliven, S.; Xie, L.; Bourne, P. E. J. Med. 
Chem. 2017, 60, 2879Ȃ2889. 
(12)  Carrera, A. C.; Alexandrov, K.; Roberts, T. M. Proc. Natl. 
Acad. Sci. U. S. A. 1993, 90, 442Ȃ446. 
(13)  Dahal, U.; Gilbert, A.; Obach, R.; Chen, J.; Garcia-Irizarry, 
C.; Schuff, B.; Starr, J.; Uccello, D.; Young, J. Med. Chem. 
Commun. 2016, 7, 864Ȃ872. 
(14)  Akçay, G.; Belmonte, M. A.; Aquila, B.; Chuaqui, C.; Hird, A. 
W.; Lamb, M. L.; Rawlins, P. B.; Su, N.; Tentarelli, S.; 
Grimster, N. P.; Su, Q. Nat. Chem. Biol. 2016, 12, 931Ȃ936. 
(15)  Anscombe, E.; Meschini, E.; Mora-vidal, R.; Stephen, R.; 
Endicott, J. A.; Griffin, R. J. Chem. Biol. 2015, 22, 1159Ȃ1164. 
(16)  Hacker, S. M.; Backus, K. M.; Lazear, M. R.; Forli, S.; 
Correia, B. E.; Cravatt, B. F. Nat. Chem. 2017, DOI: 
http://dx.doi.org/10.1038/nchem.2826 
(17)  Pettinger, J.; Jones, K.; Cheeseman, M. D. Angew. Chemie 
Int. Ed. 2017. DOI: 10.1002/anie.201707630 
(18)  Pettinger, J.; Bihan, Y.-V. Le; Widya, M.; Montfort, R. L. M. 
Van; Jones, K.; Cheeseman, M. D. Angew. Chemie Int. Ed. 
2017, 56, 3536Ȃ3540. 
(19)  Cantley, L. L. C. Science 2002, 296, 1655Ȃ1657. 
(20)  Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. 
T.; Pacold, J. I.; Gorrec, F.; Hon, W.-C.; Liu, Y.; Rommel, C.; 
Gaillard, P.; Rückle, T.; Schwarz, M. K.; Shokat, K. M.; 
Shaw, J. P.; Williams, R. L. Nat. Chem. Biol. 2010, 6, 117Ȃ124. 
(21)  Stark, A.-K.; Sriskantharajah, S.; Hessel, E. M.; Okkenhaug, 
K. Curr. Opin. Pharmacol. 2015, 23, 82Ȃ91. 
(22)  Fruman, D. A.; Chiu, H.; Hopkins, B. D.; Bagrodia, S.; 
Cantley, L. C.; Abraham, R. T. Cell 2017, 170, 605Ȃ635. 
(23)  Down, K.; Amour, A.; Baldwin, I. R.; Cooper, A. W. J.; 
Deakin, A. M.; Felton, L. M.; Guntrip, S. B.; Hardy, C.; 
Harrison, Z. A.; Jones, K. L.; Jones, P.; Keeling, S. E.; Le, J.; 
Livia, S.; Lucas, F.; Lunniss, C. J.; Parr, N. J.; Robinson, E.; 
Rowland, P.; Smith, S.; Thomas, D. A.; Vitulli, G.; Washio, 
Y.; Hamblin, J. N. J. Med. Chem. 2015, 58, 7381Ȃ7399. 
(24)  Somoza, J. R.; Koditek, D.; Villaseñor, A. G.; Novikov, N.; 
Wong, M. H.; Liclican, A.; Xing, W.; Lagpacan, L.; Wang, R.; 
Schultz, B. E.; Papalia, G. A.; Samuel, D.; Lad, L.; McGrath, 
M. E. J. Biol. Chem. 2015, 290, 8439Ȃ8446. 
(25)  Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Nat. Rev. Drug 
Discov. 2009, 8, 627Ȃ644. 
(26)  Vanhaesebroeck, B.; Whitehead, M. A.; Piñeiro, R. J. Mol. 
Med. 2016, 94, 5Ȃ11. 
(27)  Rowan, W. C.; Smith, J. L.; Affleck, K.; Amour, A. Biochem. 
Soc. Trans. 2012, 40, 240Ȃ245. 
(28)  Rommel, C.; Camps, M.; Ji, H. Nat. Rev. Immunol. 2007, 7, 
191Ȃ201. 
(29)  Koyasu, S. Nat. Immunol. 2003, 4, 313Ȃ319. 
(30)  Ghigo, A.; Damilano, F.; Braccini, L.; Hirsch, E. BioEssays 
2010, 32, 185Ȃ196. 
(31)  Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, 
S.; Peskett, E.; Pearce, W.; Meek, S. E.; Salpekar, A.; 
Waterfield, M. D.; Smith, A. J. H.; Vanhaesebroeck, B. 
Science 2002, 297, 1031Ȃ1034. 
(32)  Puri, K. D.; Doggett, T. A.; Douangpanya, J.; Hou, Y.; Tino, 
W. T.; Wilson, T.; Graf, T.; Clayton, E.; Turner, M.; Hayflick, 
J. S.; Diacovo, T. G. Blood 2004, 103, 3448Ȃ3456. 
(33)  Norman, B. H.; Shih, C.; Toth, J. E.; Ray, J. E.; Dodge, J. a.; 
Johnson, D. W.; Rutherford, P. G.; Schultz, R. M.; Worzalla, 
J. F.; Vlahos, C. J. J. Med. Chem. 1996, 39, 1106Ȃ1111. 
(34)  Waterfield, M. D.; Panayotou, G.; Wymann, M. P.; 
Bulgarelli-Leva, G.; Zvelebil, M. J.; Pirola, L.; 
Vanhaesebroeck, B. Mol. Cell. Biol. 1996, 16, 1722Ȃ1733. 
(35)  Hong, D. S.; Bowles, D. W.; Falchook, G. S.; Messersmith, 
ǤǤǢ
ǡ
ǤǤǢǯǡǤǤǢǡǤǤǤǢǡ
K.; Herbst, R. S.; Eckhardt, S. G.; Peterson, S.; Hausman, D. 
F.; Kurzrock, R.; Jimeno, A. Clin. Cancer Res. 2012, 18, 4173Ȃ
4182. 
(36)  Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; 
Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Mol. Cell 
9 
2000, 6, 909Ȃ919. 
(37)  Miller, R. M.; Taunton, J. Methods Enzymol. 2014, 548, 93Ȃ
116. 
(38)  Patricelli, M. P.; Nomanbhoy, T. K.; Wu, J.; Brown, H.; 
Zhou, D.; Zhang, J.; Jagannathan, S.; Aban, A.; Okerberg, E.; 
Herring, C.; Nordin, B.; Weissig, H.; Yang, Q.; Lee, J. D.; 
Gray, N. S.; Kozarich, J. W. Chem. Biol. 2011, 18, 699Ȃ710. 
(39)  Cravatt, B. F.; Wright, A. T.; Kozarich, J. W. Annu. Rev. 
Biochem. 2008, 77, 383Ȃ414. 
(40)  Zhao, Q.; Ouyang, X.; Wan, X.; Gajiwala, K. S.; Kath, J. C.; 
Jones, L. H.; Burlingame, A. L.; Taunton, J. J. Am. Chem. 
Soc. 2017, 139, 680Ȃ685. 
(41)  Patricelli, M. P.; Szardenings, A. K.; Liyanage, M.; 
Nomanbhoy, T. K.; Wu, M.; Weissig, H.; Aban, A.; Chun, 
D.; Tanner, S.; Kozarich, J. W. Biochemistry 2007, 46, 350Ȃ
358. 
(42)  Choi, S.; Connelly, S.; Reixach, N.; Wilson, I. A.; Kelly, J. W. 
Nat. Chem. Biol. 2010, 6, 133Ȃ139. 
(43)  Hansch, C.; Leo, A.; Taft, R. W. Chem. Rev. 1991, 91, 165Ȃ195. 
(44)  Sutherlin, D. P.; Baker, S.; Bisconte, A.; Blaney, P. M.; 
Brown, A.; Chan, B. K.; Chantry, D.; Castanedo, G.; 
Depledge, P.; Goldsmith, P.; Goldstein, D. M.; Hancox, T.; 
Kaur, J.; Knowles, D.; Kondru, R.; Lesnick, J.; Lucas, M. C.; 
Lewis, C.; Murray, J.; Nadin, A. J.; Nonomiya, J.; Pang, J.; 
Pegg, N.; Price, S.; Reif, K.; Safina, B. S.; Salphati, L.; Staben, 
S.; Seward, E. M.; Shuttleworth, S.; Sohal, S.; Sweeney, Z. K.; 
Ultsch, M.; Waszkowycz, B.; Wei, B. Bioorganic Med. Chem. 
Lett. 2012, 22, 4296Ȃ4302. 
(45)  Charter, N. W.; Kauffman, L.; Singh, R. A. J.; Eglen, R. M. J. 
Biomol. Screen. 2006, 11, 390Ȃ399. 
(46)  Copeland, R. A. Enzymes: A Practical Introduction to 
Structure, Mechanism and Data Analysis, Ch. 10 (Wiley, 
New York, NY, USA, 2000) 
(47)  Kitz, R.; Wilson, B. J. Biol. Chem. 1962, 237, 3245Ȃ3249. 
(48)  Strelow, J. M. SLAS Discov. 2017, 22, 3Ȃ20. 
(49)  Schwartz, P. A.; Kuzmic, P.; Solowiej, J.; Bergqvist, S.; 
Bolanos, B.; Almaden, C.; Nagata, A.; Ryan, K.; Feng, J.; 
Dalvie, D.; Kath, J. C.; Xu, M.; Wani, R.; Murray, B. W. Proc. 
Natl. Acad. Sci. U. S. A. 2014, 111, 173Ȃ178. 
(50)  Weerapana, E.; Wang, C.; Simon, G. M.; Richter, F.; Khare, 
S.; Dillon, M. B. D.; Bachovchin, D. A.; Mowen, K.; Baker, 
D.; Cravatt, B. F. Nature 2010, 468, 790Ȃ795. 
(51)  Backus, K. M.; Correia, B. E.; Lum, K. M.; Forli, S.; Horning, 
B. D.; González-Páez, G. E.; Chatterjee, S.; Lanning, B. R.; 
Teijaro, J. R.; Olson, A. J.; Wolan, D. W.; Cravatt, B. F. 
Nature 2016, 534, 570Ȃ574. 
(52)  Rutkowska, A.; Thomson, D. W.; Vappiani, J.; Werner, T.; 
Mueller, K. M.; Dittus, L.; Krause, J.; Muelbaier, M.; 
Bergamini, G.; Bantscheff, M. ACS Chem. Biol. 2016, 11, 
2541Ȃ2550. 
(53)  Lanning, B. R.; Whitby, L. R.; Dix, M. M.; Douhan, J.; 
Gilbert, A. M.; Hett, E. C.; Johnson, T. O.; Joslyn, C.; Kath, J. 
C.; Niessen, S.; Roberts, L. R.; Schnute, M. E.; Wang, C.; 
Hulce, J. J.; Wei, B.; Whiteley, L. O.; Hayward, M. M.; 
Cravatt, B. F. Nat. Chem. Biol. 2014, 10, 760Ȃ767. 
(54)  Niessen, S.; Dix, M. M.; Barbas, S.; Hayward, M. M.; Kath, J. 
C.; Cravatt, B. F.; Niessen, S.; Dix, M. M.; Barbas, S.; Potter, 
Z. E.; Lu, S.; Brodsky, O. Cell Chem. Biol. 2017, 24, 1Ȃ13. 
(55)  Yu, X.; Long, Y. C.; Shen, H. M. Autophagy 2015, 11, 1711Ȃ
1728. 
(56)  Klaeger, S.; Gohlke, B.; Perrin, J.; Gupta, V.; Heinzlmeir, S.; 
Helm, D.; Qiao, H.; Bergamini, G.; Handa, H.; Savitski, M. 
M.; Bantscheff, M.; Médard, G.; Preissner, R.; Kuster, B. ACS 
Chem. Biol. 2016, 11, 1245Ȃ1254. 
(57)  Cahn, A.; Hamblin, J. N.; Begg, M.; Wilson, R.; Dunsire, L.; 
Sriskantharajah, S.; Montembault, M.; Leemereise, C. N.; 
Galinanes-Garcia, L.; Watz, H.; Kirsten, A. M.; Fuhr, R.; 
Hessel, E. M. Pulm. Pharmacol. Ther. 2017, 46, 69Ȃ77. 
(58)  Kazmi, F.; Hensley, T.; Pope, C.; Funk, R. S.; Loewen, G. J.; 
Buckley, D. B.; Parkinson, A. Drug Metab. Dispos. 2013, 41, 
897Ȃ905. 
(59)  Thorarensen, A.; Dowty, M. E.; Banker, M. E.; Juba, B. M.; 
Jussif, J.; Lin, T.; Vincent, F.; Czerwinski, R. M.; Casimiro-
Garcia, A.; Unwalla, R.; Trujillo, J. I.; Liang, S.; Balbo, P.; 
Che, Y.; Gilbert, A. M.; Brown, M. F.; Hayward, M.; 
Montgomery, J.; Leung, L.; Yang, X.; Soucy, S.; Hegen, M.; 
Coe, J.; Langille, J.; Vajdos, F. F.; Chrencik, J. E.; Telliez, J.-B. 
J. Med. Chem. 2017, 60, 1971Ȃ1993. 
(60)  Engel, J.; Lategahn, J.; Rauh, D. ACS Med. Chem. Lett. 2016, 
7, 2Ȃ5. 
(61)  Iyer, G. H.; Moore, M. J.; Taylor, S. S. J. Biol. Chem. 2005, 
280, 8800Ȃ8807. 
(62)  Zaro, B. W.; Whitby, L. R.; Lum, K. M.; Cravatt, B. F. J. Am. 
Chem. Soc. 2016, 138, 15841Ȃ15844. 
 
 
